Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Other Operating Expenses (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other Operating Expenses for 11 consecutive years, with -$2000.0 as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 200.0% to -$2000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Dec 2025, down 19.46% year-over-year, with the annual reading at -$4000.0 for FY2025, 93.94% up from the prior year.
  • Other Operating Expenses for Q4 2025 was -$2000.0 at Gyre Therapeutics, down from -$1000.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was $68.7 million in Q4 2021, with the low at -$2.2 million in Q4 2023.
  • Average Other Operating Expenses over 5 years is $9.3 million, with a median of $798000.0 recorded in 2022.
  • The sharpest move saw Other Operating Expenses surged 4925.9% in 2022, then crashed 3584.75% in 2023.
  • Over 5 years, Other Operating Expenses stood at $68.7 million in 2021, then tumbled by 100.09% to -$59000.0 in 2022, then plummeted by 3584.75% to -$2.2 million in 2023, then skyrocketed by 100.09% to $2000.0 in 2024, then plummeted by 200.0% to -$2000.0 in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$2000.0, -$1000.0, and -$1000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.